Steven Daniel joins Cofactor Genomics as Vice President of Business Development

— Leading Cofactor’s commercial efforts to grow the Predictive Immune Modeling market   — San Francisco, June 20, 2019 (REPORTABLE) — Cofactor Genomics today announced the appointment of Steven Daniel, PhD as Vice President of Business Development, overseeing the development and execution of the company’s sales strategy and sales management. Dr. Daniel comes to Cofactor from... Read more

Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery

— Contributing to both the Cancer and Inflammation and Immunity Steering Committees —SAN FRANCISCO, June. 4, 2019 (BUSINESS WIRE) – Cofactor Genomics, pioneers in the field of Predictive Immune Modeling, announced today that they have become a member of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium with the goal of advancing... Read more

Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences

— Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial —December 04, 2018 09:00 AM Eastern Standard Time SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, a clinical RNA sequencing and translational assay developer, today announced a pilot study to evaluate use of Cofactor’s ImmunoPrismTM assay in Genocea Biosciences’ Phase 1/2a clinical trial testing the... Read more

Cofactor Genomics Launches ImmunoPrism™ Immune Profiling Kit, for Use in Clinical Sequencing Laboratories

October 30, 2018 08:00 ET | Source: Cofactor Genomics –Enables in-house, RNA-based, solid tumor profiling with powerful, cloud-based informatics tools to inform critical clinical decisions– SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) — Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the launch of a RNA-based immune profiling kit developed for laboratories wishing to derive... Read more